Notfälle
Blutspende
Karriere
Presse
Forschung
Lehre
Patienten
Zuweiser

Popadic D, Anegon I, Baeten D, Eibel H, Giese T, Marits P, Martinez-Caceres E, Mascart F, Nestle F, Pujol-Borrell R, Savic E, Scheibenbogen C, Seliger B, Thunberg S, Turina M, Villanova F, Winqvist O, Wikström A. Predictive immunomonitoring - the COST ENTIRE initiative. Clin Immunol. 2013; 147(1):23-26.

 

Massa C, Seliger B. Fast Dendritic Cells Stimulated with Alternative Maturation Mixtures Induce Polyfunctional and Long-Lasting Activation of Innate and Adaptive Effector Cells with Tumor-Killing Capabilities. J Immunol. 2013; 190(7):3328-37.

 

Mueller M, Agaimy A, Zenk J, Ettl T, Hartmann A, Seliger B, Schwarz S. The prognostic impact of human leucocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinic-pathological study of 288 cases. Histopathology. 2013; 62(6):847-59.

 

Stoehr C, Buettner-Herold M, Kamphausen E, Bertz S, Hartmann A, Seliger B. Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes. Int J Clin Exp Pathol. 2013; 6(6): 998-1008.

 

Stehle F, Schulz K, Fahldieck C, Kalich J,  Lichtenfels R, Riemann D, Seliger B. Reduced immune-suppressive properties of axitinib in comparison to other tyrosine kinase inhibitors. J Biol Chem. 2013; 288(23): 16334-47.

 

Ascierto P, Grimaldi A, Acquavella N, Borgognoni L, Calabro L, Cascinelli N, Cesan A, del Vecchio M, Eggermont A, Faries M, Ferrone S, Fox B, Gajeweski T, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman H, Larkin J, Lo R, Mantovani A, Margolin K, Melief C,  McArthur G, Palmieri G, Puzano I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini A, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola F, Thurin M. Future Perspectives in melanoma research. Meeting report from the “Melanoma Bridge”. Napoli, December 2nd-4th 2012”. J Transl Med. 2013 Jun 3;11(1):137.

 

Wulfaenger J, Biehl K, Tetzner A, Wild P, Ikenberg K, Meyer S, Seliger B. Heterogeneous expression and functional relevance of the ubiquitin carboxylterminal hydrolase L1 in melanoma. Int J Cancer. 2013 May 17 Dec 1;133(11):2522-32.

 

Seliger B, Kiessling R. The two sides of HER2/neu: immune escape versus surveillance. Trends in Mol Medicine. 2013 Nov;19(11):677-84.

 

Steven A, Leisz S, Massa C, Iezzi M, Lattanzio R, Lamolinara A, Bukur J, Mueller A, Hiebl B, Holzhausen H, Seliger B. HER-2/neu mediates oncogenic transformation via altered CREB expression and function. Mol Cancer Res. 2013 Nov;11(11):1462-77.

 

Marchesi M, Andersson E, Villabona L, Seliger B, Lundqvist A, Kiessling R, Masucci GV. HLA-dependent tumour development: a role for tumour associate macrophages? J Transl Med. 2013 Oct;11:247.

 

Mimura K, Shiraishi K, Mueller A, Izawa S, Kua LF, So J, Yong WP, Fujii H, Seliger B, Kiessling R, Kono K. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol. 2013 Dec 15;191(12):6261-72.

 

Seliger B, Massa C. The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape. Front Immunol. 2013 Dec;4:419.

 

Seliger B. The non-classical antigens of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors. Clin Transpl. 2013:465-72.